<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1426">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323334</url>
  </required_header>
  <id_info>
    <org_study_id>15562</org_study_id>
    <secondary_id>I7X-EW-LLCA</secondary_id>
    <nct_id>NCT02323334</nct_id>
  </id_info>
  <brief_title>A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease</brief_title>
  <official_title>Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves single and multiple doses of LY3202626 and will evaluate the effects of&#xD;
      LY3202626 on the body. There will be 4 parts to this study. In Parts A and B, single&#xD;
      increasing doses of LY3202626 will be given in capsule form. Part A will also include&#xD;
      itraconazole given orally as a solution. Part A will last approximately 8-12 weeks. Part B&#xD;
      will last approximately 5-6 weeks. In Parts C and D, participants will be dosed multiple days&#xD;
      with the study drug. Part C will last approximately 11-14 weeks. Part D will last&#xD;
      approximately 11-14 weeks and participants must have Alzheimer's Disease. Participants may&#xD;
      only enroll in one part.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline to Study Completion (up to 14 weeks)</time_frame>
    <description>A summary of other nonserious Adverse Events (AE's), and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3202626</measure>
    <time_frame>Part A and B Day 1:Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose; Part C Day 1:Predose, 0.5,1, 2, 4, 6, 8, and 12 hours postdose; Part C Day 14:Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 216 hours postdose</time_frame>
    <description>Summary of PK parameters of LY3202626 in plasma following oral administration of single doses for Parts A and B and multiple doses for Part C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Time Curve (AUC) of LY3202626</measure>
    <time_frame>Part A and B Day 1: Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose; Part C Day 1:Presdose, 0.5,1, 2, 4, 6, 8,12 hours postdose; Day 14: Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 216 hours postdose</time_frame>
    <description>Pharmacokinetic parameters for Part A and B were assessed on Day 1 using AUC 0-infinity (AUC0-inf). Pharmacokinetic parameters for Part C were assessed on Day 1 using AUC zero to time to last (AUC0-tlast), Day 14 using AUC steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic(PD) Biomarker: Plasma Minimum Amyloid-Beta Peptide (A-beta) 1-40 Concentration</measure>
    <time_frame>Part A Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 postdose; Part C Day 14: Predose 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 120, 168, and 216 postdose</time_frame>
    <description>Plasma minimum A-beta 1-40 concentration or nadir concentration (Cnadir) is defined as the lowest concentration of plasma A-beta 1-40 following dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Biomarker: Cerebral Spinal Fluid (CSF) Minimum Amyloid-beta Peptide (A-beta) 1-40 Concentration</measure>
    <time_frame>Part B: -4, -2, Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 24, 28, 32, and 36 hours postdose</time_frame>
    <description>CSF minimum A-beta 1-40 concentration or nadir concentration (Cnadir) is defined as the lowest concentration of CSF A-beta 1-40 following dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: CSF Concentration of LY3202626</measure>
    <time_frame>Part C: Day 15 at 24 hours +/- 4 hours (hr) postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Biomarker: Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid-beta Peptide (A-beta) 1-40 Concentration</measure>
    <time_frame>Parts C: Baseline, Day 15</time_frame>
    <description>CSF AÎ²1-40 change from baseline at Day 15 endpoint, 24 hours postdose (+/- 4 hours) following multiple doses of LY3202626.</description>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.&#xD;
Period 1: 0.1mg LY3202626 Period 2: 1.6mg LY3202626 Period 3: 15 mg placebo (PBO) Period 4: 15mg LY3202626.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.&#xD;
Period 1: 0.1mg Period 2: PBO Period 3: 15mg LY3202626 Period 4: 15mg LY3202626.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.&#xD;
Period 1: PBO Period 2: 1.6mg LY3202626 Period 3: 15mg LY3202626 Period 4: PBO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.&#xD;
Period 1: 0.4mg LY3202626 Period 2: 5mg LY3202626 Period 3: 45mg, PBO Period 4: 0.4mg LY3202626/200mg Itraconazole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.&#xD;
Period 1: 0.4mg LY3202626 Period 2: 5mg, PBO Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.&#xD;
Period 1: 0.4mg, PBO Period 2: 5mg LY3202626 Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose of 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fed 2: Fasted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fasted 2: Fed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort 4: 1.6mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B Cohort 4 involved healthy participants and was comprised of one period. Single dose of 1.6mg LY3202626 given PO in Period 1. Dose determined by Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort 5: 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B Cohort 5 involved healthy participants and was comprised of one period. Single dose of 10mg LY3202626 given PO in Period 1. Dose determined by Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort 6: 26mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B Cohort 6 involved healthy participants and was comprised of one period. Single dose of 26mg LY3202626 given PO in Period 1. Dose determined by Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort 4, 5, 6: Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B Cohort 4,5,6 involved healthy participants and was comprised of one period. Single dose of PBO given PO in Period 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Cohort 7: 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C Cohort 7 involved healthy participants and was comprised of one period. 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Cohort 8: 6mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C Cohort 8 involved healthy participants and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Cohort 9: 26mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C Cohort 9 included healthy participants and was comprised of one period. 26mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Cohort 7, 8 ,9: Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part C Cohort 7,8,9 involved healthy participants and was comprised of one period. Placebo given PO once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D Cohort 10: 6mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part D Cohort 10 involved participants with Alzheimer's disease and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3202626</intervention_name>
    <description>administered orally</description>
    <arm_group_label>Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg</arm_group_label>
    <arm_group_label>Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo</arm_group_label>
    <arm_group_label>Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg</arm_group_label>
    <arm_group_label>Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole</arm_group_label>
    <arm_group_label>Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra</arm_group_label>
    <arm_group_label>Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra</arm_group_label>
    <arm_group_label>Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted</arm_group_label>
    <arm_group_label>Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed</arm_group_label>
    <arm_group_label>Part B Cohort 4: 1.6mg</arm_group_label>
    <arm_group_label>Part B Cohort 5: 10mg</arm_group_label>
    <arm_group_label>Part B Cohort 6: 26mg</arm_group_label>
    <arm_group_label>Part C Cohort 7: 1mg</arm_group_label>
    <arm_group_label>Part C Cohort 8: 6mg</arm_group_label>
    <arm_group_label>Part C Cohort 9: 26mg</arm_group_label>
    <arm_group_label>Part D Cohort 10: 6mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part A, B, C)</intervention_name>
    <description>administered orally</description>
    <arm_group_label>Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg</arm_group_label>
    <arm_group_label>Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo</arm_group_label>
    <arm_group_label>Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg</arm_group_label>
    <arm_group_label>Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole</arm_group_label>
    <arm_group_label>Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra</arm_group_label>
    <arm_group_label>Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra</arm_group_label>
    <arm_group_label>Part B Cohort 4, 5, 6: Placebo Comparator</arm_group_label>
    <arm_group_label>Part C Cohort 7, 8 ,9: Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>administered orally</description>
    <arm_group_label>Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra</arm_group_label>
    <arm_group_label>Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Parts A, B, and C, are overtly healthy males or females (nonchildbearing&#xD;
             potential), as determined by medical history and physical examination&#xD;
&#xD;
          -  Have a body mass index (BMI) of 18 to 32 kilograms per square meter (kg/m^2)&#xD;
&#xD;
          -  For Part D, present with Mild Cognitive Impairment (MCI) due to Alzheimer's Disease&#xD;
             (AD) or mild to moderate AD&#xD;
&#xD;
          -  Have venous access sufficient to allow for blood sampling&#xD;
&#xD;
          -  Are reliable and willing to make themselves available for the duration of the study&#xD;
             and are willing to follow study procedures and research unit policies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking over-the-counter or prescription medication with the exception of vitamins or&#xD;
             minerals&#xD;
&#xD;
          -  Smoke more than 10 cigarettes per day&#xD;
&#xD;
          -  Are unwilling or unable to refrain from eating any food or drinking any beverage&#xD;
             containing grapefruit or grapefruit juice for at least 2 weeks prior to first dose&#xD;
             until completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <results_first_submitted>March 22, 2021</results_first_submitted>
  <results_first_submitted_qc>March 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2021</results_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part A Cohort 1 Sequence 1: 0.1mg, 1.6mg, Placebo (PBO); 15mg</title>
          <description>Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods. There was a washout period of approximately 14 days between doses.&#xD;
Period 1: 0.1mg LY3202626 Period 2: 1.6mg LY3202626 Period 3: 15 mg PBO Period 4: 15mg LY3202626</description>
        </group>
        <group group_id="P2">
          <title>Part A Cohort 1 Sequence 2: 1.6mg, PBO,15mg, 15mg</title>
          <description>Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods. There was a washout period of approximately 14 days between doses.&#xD;
Period 1: 1.6mg LY3202626 Period 2: PBO Period 3: 15mg LY3202626 Period 4: 15mg LY3202626</description>
        </group>
        <group group_id="P3">
          <title>Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, PBO</title>
          <description>Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods. There was a washout period of approximately 14 days between doses.&#xD;
Period 1: PBO Period 2: 1.6mg LY3202626 Period 3: 15mg LY3202626 Period 4: PBO</description>
        </group>
        <group group_id="P4">
          <title>Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO; 0.4mg/200mg Itra</title>
          <description>Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods. Period 4 includes 0.4mg LY3202626 and 200mg Itraconazole (Itra). There was a washout period of approximately 14 days between doses.&#xD;
Period 1: 0.4mg LY3202626 Period 2: 5mg LY3202626 Period 3: 45mg PBO Period 4: 0.4mg LY3202626/200mg Itraconazole</description>
        </group>
        <group group_id="P5">
          <title>Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/200mg Itra</title>
          <description>Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods. Period 4 includes 0.4mg LY3202626 and 200mg Itraconazole.There was a washout period of approximately 14 days between doses.&#xD;
Period 1: 0.4mg LY3202626 Period 2: 5mg PBO Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole</description>
        </group>
        <group group_id="P6">
          <title>Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra</title>
          <description>Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods. Period 4 includes 0.4mg LY3202626 and 200mg Itraconazole. There was a washout period of approximately 14 days between doses.&#xD;
Period 1: 0.4mg PBO Period 2: 5mg LY3202626 Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole</description>
        </group>
        <group group_id="P7">
          <title>Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted</title>
          <description>Part A Cohort 3 involved healthy participants and was comprised of two treatment periods. Single dose of 10mg LY3202626 given PO in Period 1 and 2. There was a washout period of approximately 14 days between doses.&#xD;
Period 1: Fed Period 2: Fasted</description>
        </group>
        <group group_id="P8">
          <title>Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed</title>
          <description>Part A Cohort 3 involved healthy participants and was comprised of two treatment periods. Single dose 10mg LY3202626 given PO in Period 1 and 2.&#xD;
There was a washout period of approximately 14 days between doses.&#xD;
Period 1: Fasted Period 2: Fed</description>
        </group>
        <group group_id="P9">
          <title>Part B Cohort 4: 1.6mg</title>
          <description>Part B Cohort 4 involved healthy participants and was comprised of one period. Single dose of 1.6mg LY3202626 given PO in Period 1. Dose determined by Part A.</description>
        </group>
        <group group_id="P10">
          <title>Part B Cohort 5: 10mg</title>
          <description>Part B Cohort 5 involved healthy participants and was comprised of one period. Single dose of 10mg LY3202626 given PO in Period 1. Dose determined by Part A.</description>
        </group>
        <group group_id="P11">
          <title>Part B Cohort 6: 26mg</title>
          <description>Part B Cohort 6 involved healthy participants and was comprised of one period. Single dose of 26mg LY3202626 given PO in Period 1. Dose determined by Part A.</description>
        </group>
        <group group_id="P12">
          <title>Part B Cohort 4, 5, 6: PBO Comparator</title>
          <description>Part B Cohort 4,5,6 involved healthy participants and was comprised of one period. Single dose of PBO given PO in Period 1.</description>
        </group>
        <group group_id="P13">
          <title>Part C Cohort 7: 1mg</title>
          <description>Part C Cohort 7 involved healthy participants and was comprised of one period. 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.</description>
        </group>
        <group group_id="P14">
          <title>Part C Cohort 8: 6mg</title>
          <description>Part C Cohort 8 involved healthy participants and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.</description>
        </group>
        <group group_id="P15">
          <title>Part C Cohort 9: 26mg</title>
          <description>Part C Cohort 9 included healthy participants and was comprised of one period. 26mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.</description>
        </group>
        <group group_id="P16">
          <title>Part C Cohort 7, 8 ,9: PBO Comparator</title>
          <description>Part C Cohort 7, 8, 9 involved healthy participants and was comprised of one period. PBO given PO once daily for 14 days.</description>
        </group>
        <group group_id="P17">
          <title>Part D Cohort 10: 6mg</title>
          <description>Part D Cohort 10 involved participants with Alzheimer's disease and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="9"/>
                <participants group_id="P14" count="9"/>
                <participants group_id="P15" count="9"/>
                <participants group_id="P16" count="9"/>
                <participants group_id="P17" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="9"/>
                <participants group_id="P14" count="9"/>
                <participants group_id="P15" count="9"/>
                <participants group_id="P16" count="9"/>
                <participants group_id="P17" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="9"/>
                <participants group_id="P14" count="9"/>
                <participants group_id="P15" count="9"/>
                <participants group_id="P16" count="9"/>
                <participants group_id="P17" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="0">Part B was a single period conducted in parallel to Part A and received last dose in Period 1.</participants>
                <participants group_id="P10" count="0">Part B was a single period conducted in parallel to Part A and received last dose in Period 1.</participants>
                <participants group_id="P11" count="0">Part B was a single period conducted in parallel to Part A and received last dose in Period 1.</participants>
                <participants group_id="P12" count="0">Part B was a single period conducted in parallel to Part A and received last dose in Period 1.</participants>
                <participants group_id="P13" count="0">Part C was a single period conducted in parallel to Part A and received last dose in Period 1.</participants>
                <participants group_id="P14" count="0">Part C was a single period conducted in parallel to Part A and received last dose in Period 1.</participants>
                <participants group_id="P15" count="0">Part C was a single period conducted in parallel to Part A and received last dose in Period 1.</participants>
                <participants group_id="P16" count="0">Part C was a single period conducted in parallel to Part A and received last dose in Period 1.</participants>
                <participants group_id="P17" count="0">Part D was a single period conducted in parallel to Part A and received last dose in Period 1.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0">Part A Cohort 3 Food Effect participated in Period 1 and Period 2 only.</participants>
                <participants group_id="P8" count="0">Part A Cohort 3 Food Effect participated in Period 1 and Period 2 only.</participants>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A Cohort 1</title>
          <description>Escalating single dose given orally (PO)per randomly assigned treatment sequence of 0.1mg, 1.6mg, 15mg LY3202626 or placebo.</description>
        </group>
        <group group_id="B2">
          <title>Part A Cohort 2</title>
          <description>Escalating single dose given PO per randomly assigned treatment sequence of 0.4mg, 5mg, or 45mg LY3202626, placebo.&#xD;
Some participants may also receive multiple doses of 200 mg of Itraconazole PO in 1 period with 0.4mg of LY3202626.</description>
        </group>
        <group group_id="B3">
          <title>Part A Food Effect Cohort 3</title>
          <description>Single dose of 10mg LY3202626 given PO in Period 1 and Period 2 only.</description>
        </group>
        <group group_id="B4">
          <title>Part B Cohort 4</title>
          <description>Single oral dose of 1.6mg LY3202626 or placebo given PO in Period 1. Dose determined by Part A.</description>
        </group>
        <group group_id="B5">
          <title>Part B Cohort 5</title>
          <description>Single oral dose of 10mg LY3202626 or placebo given PO in in Period 1. Dose determined by Part A.</description>
        </group>
        <group group_id="B6">
          <title>Part B Cohort 6</title>
          <description>Single oral dose of 26mg LY3202626 or placebo given PO in Period 1. Dose determined by Part A.</description>
        </group>
        <group group_id="B7">
          <title>Part C Cohort 7</title>
          <description>Multiple oral doses of 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.</description>
        </group>
        <group group_id="B8">
          <title>Part C Cohort 8</title>
          <description>Multiple oral doses of 6mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.</description>
        </group>
        <group group_id="B9">
          <title>Part C Cohort 9</title>
          <description>Multiple oral doses of 26mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.</description>
        </group>
        <group group_id="B10">
          <title>Part D Cohort 10</title>
          <description>Multiple oral doses of 6mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="12"/>
            <count group_id="B9" value="12"/>
            <count group_id="B10" value="2"/>
            <count group_id="B11" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.0" spread="8.1"/>
                    <measurement group_id="B2" value="36.9" spread="8.4"/>
                    <measurement group_id="B3" value="39.0" spread="13.6"/>
                    <measurement group_id="B4" value="36.5" spread="12.4"/>
                    <measurement group_id="B5" value="43.0" spread="11.3"/>
                    <measurement group_id="B6" value="35.2" spread="7.2"/>
                    <measurement group_id="B7" value="37.5" spread="10.5"/>
                    <measurement group_id="B8" value="40.4" spread="8.1"/>
                    <measurement group_id="B9" value="40.5" spread="10.5"/>
                    <measurement group_id="B10" value="68.0" spread="2.8"/>
                    <measurement group_id="B11" value="38.70" spread="10.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="11"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
        <description>A summary of other nonserious Adverse Events (AE's), and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
        <time_frame>Baseline to Study Completion (up to 14 weeks)</time_frame>
        <population>All participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A, B, and C Placebo (PBO)</title>
            <description>Single dose placebo given PO in Part A and B. Multiple doses of PBO given PO in Part C.</description>
          </group>
          <group group_id="O2">
            <title>Part A 0.1mg LY3202626</title>
            <description>Single dose of 0.1mg LY3202626 given PO Period 1 Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A 0.4mg LY3202626</title>
            <description>Single dose of 0.4mg LY3202626 given PO in Period 1 Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part A 0.4mg LY3202626 + 200mg Itraconazole</title>
            <description>Single dose of 0.4mg LY3202626 +200mg Itraconazole given PO in Period 4 Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>Part C 1mg LY3202626 QD</title>
            <description>Multiple daily dose of 1mg LY3202626 given PO once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Part A and B 1.6mg LY3202626</title>
            <description>Single dose of 1.6mg LY3202626 given PO in Period 2 Cohort 1 in Part A and Period 1 Part B.</description>
          </group>
          <group group_id="O7">
            <title>Part A 5mg LY3202626</title>
            <description>Single dose of 5mg LY3202626 given PO in in Period 2 Cohort 2.</description>
          </group>
          <group group_id="O8">
            <title>Part C and D 6mg LY3202626 QD</title>
            <description>Multiple daily dose of 6mg LY3202626 given PO once daily for 14 days.</description>
          </group>
          <group group_id="O9">
            <title>Part A, B and C 10mg LY3202626</title>
            <description>Single dose of 10mg LY3202626 given PO in Part A and B. Multiple dose of 10mg LY3202626 given PO in Part C once daily for 14 days.</description>
          </group>
          <group group_id="O10">
            <title>Part A 15mg LY3202626</title>
            <description>Single dose of 15mg LY3202626 given PO in Period 3 Cohort 1.</description>
          </group>
          <group group_id="O11">
            <title>Part B and C 26mg LY3202626</title>
            <description>Single dose of 26mg LY3202626 given PO in Period 1 in Part B. Multiple daily dose of 26mg LY3202626 given PO once daily for 14 days in Part C.</description>
          </group>
          <group group_id="O12">
            <title>Part A 45mg LY3202626</title>
            <description>Single dose of 45mg LY3202626 given PO in in Period 3 Cohort 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
          <description>A summary of other nonserious Adverse Events (AE's), and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
          <population>All participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="19"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="14"/>
                <count group_id="O12" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3202626</title>
        <description>Summary of PK parameters of LY3202626 in plasma following oral administration of single doses for Parts A and B and multiple doses for Part C.</description>
        <time_frame>Part A and B Day 1:Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose; Part C Day 1:Predose, 0.5,1, 2, 4, 6, 8, and 12 hours postdose; Part C Day 14:Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 216 hours postdose</time_frame>
        <population>All participants in Part A, B, and C who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A 0.1mg LY3202626</title>
            <description>Single dose of 0.1mg LY3202626 given PO in Period 1 Cohort 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A 0.4mg LY3202626</title>
            <description>Single dose of 0.4mg LY3202626 given PO in Period 1 Cohort 2.</description>
          </group>
          <group group_id="O3">
            <title>Part A 1.6mg LY3202626</title>
            <description>Single dose of 1.6mg LY3202626 given PO in Period 2 Cohort 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A 5mg LY3202626</title>
            <description>Single dose of 5mg LY3202626 given PO in Period 2 Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>Part A 15mg LY3202626</title>
            <description>Single dose of 15mg LY3202626 given PO in Period 3 Cohort 1.</description>
          </group>
          <group group_id="O6">
            <title>Part A 45mg LY3202626</title>
            <description>Single dose of 45mg LY3202626 given PO in Period 3 Cohort 2.</description>
          </group>
          <group group_id="O7">
            <title>Part B 1.6mg LY3202626</title>
            <description>Single dose of 1.6mg LY3202626 given PO Period 1.</description>
          </group>
          <group group_id="O8">
            <title>Part B 10mg LY3202626</title>
            <description>Single dose of 10mg LY3202626 given PO in Period 1.</description>
          </group>
          <group group_id="O9">
            <title>Part B 26mg LY3202626</title>
            <description>Single dose of 26mg LY3202626 given PO in Period1.</description>
          </group>
          <group group_id="O10">
            <title>Part C 1mg LY3202626 QD</title>
            <description>Multiple doses of 1mg LY3202626 given PO once daily for 14 days.</description>
          </group>
          <group group_id="O11">
            <title>Part C 6mg LY3202626 QD</title>
            <description>Multiple doses of 6mg LY3202626 given PO once daily for 14 days.</description>
          </group>
          <group group_id="O12">
            <title>Part C 26mg LY3202626 QD</title>
            <description>Multiple doses of 26mg LY3202626 given PO once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3202626</title>
          <description>Summary of PK parameters of LY3202626 in plasma following oral administration of single doses for Parts A and B and multiple doses for Part C.</description>
          <population>All participants in Part A, B, and C who received at least one dose of study drug and had evaluable PK data.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.169" spread="50"/>
                    <measurement group_id="O2" value="0.486" spread="81"/>
                    <measurement group_id="O3" value="2.89" spread="70"/>
                    <measurement group_id="O4" value="7.91" spread="56"/>
                    <measurement group_id="O5" value="21.3" spread="77"/>
                    <measurement group_id="O6" value="92.5" spread="47"/>
                    <measurement group_id="O7" value="2.90" spread="86"/>
                    <measurement group_id="O8" value="3.75" spread="176"/>
                    <measurement group_id="O9" value="36.1" spread="126"/>
                    <measurement group_id="O10" value="2.57" spread="2.5"/>
                    <measurement group_id="O11" value="11.2" spread="71"/>
                    <measurement group_id="O12" value="72.8" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Area Under the Concentration Time Curve (AUC) of LY3202626</title>
        <description>Pharmacokinetic parameters for Part A and B were assessed on Day 1 using AUC 0-infinity (AUC0-inf). Pharmacokinetic parameters for Part C were assessed on Day 1 using AUC zero to time to last (AUC0-tlast), Day 14 using AUC steady state.</description>
        <time_frame>Part A and B Day 1: Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours postdose; Part C Day 1:Presdose, 0.5,1, 2, 4, 6, 8,12 hours postdose; Day 14: Predose, 0.5,1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 216 hours postdose</time_frame>
        <population>All participants in Parts A, B, and C who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A 0.1mg LY3202626</title>
            <description>Single dose of 0.1mg LY3202626 given PO in Period 1 Cohort 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A 0.4mg LY3202626</title>
            <description>Single dose of 0.4mg LY3202626 given PO in Period 1 Cohort 2.</description>
          </group>
          <group group_id="O3">
            <title>Part A 1.6mg LY3202626</title>
            <description>Single dose of 1.6mg LY3202626 given PO in Period 2 Cohort 1.</description>
          </group>
          <group group_id="O4">
            <title>Part A 5mg LY3202626</title>
            <description>Single dose of 5mg LY3202626 given PO in Period 2 Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>Part A 15mg LY3202626</title>
            <description>Single dose of 15mg LY3202626 given PO in Period 3 Cohort 1.</description>
          </group>
          <group group_id="O6">
            <title>Part A 45mg LY3202626</title>
            <description>Single dose of 45mg LY3202626 given PO in Period 3 Cohort 2.</description>
          </group>
          <group group_id="O7">
            <title>Part B 1.6mg LY3202626</title>
            <description>Single dose of 1.6mg LY3202626 given PO in Period 1.</description>
          </group>
          <group group_id="O8">
            <title>Part B 10mg LY3202626</title>
            <description>Single dose of 10mg LY3202626 given PO in Period 1.</description>
          </group>
          <group group_id="O9">
            <title>Part B 26mg LY3202626</title>
            <description>Single dose of 26mg LY3202626 given PO in Period 1.</description>
          </group>
          <group group_id="O10">
            <title>Part C 1mg LY3202626 QD</title>
            <description>Multiple doses of 1mg LY3202626 given PO once daily for 14 days..</description>
          </group>
          <group group_id="O11">
            <title>Part C 6mg LY3202626 QD</title>
            <description>Multiple doses of 6mg LY3202626 given PO once daily for 14 days.</description>
          </group>
          <group group_id="O12">
            <title>Part C 26mg LY3202626 QD</title>
            <description>Multiple doses of 26mg LY3202626 given PO once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under the Concentration Time Curve (AUC) of LY3202626</title>
          <description>Pharmacokinetic parameters for Part A and B were assessed on Day 1 using AUC 0-infinity (AUC0-inf). Pharmacokinetic parameters for Part C were assessed on Day 1 using AUC zero to time to last (AUC0-tlast), Day 14 using AUC steady state.</description>
          <population>All participants in Parts A, B, and C who received at least one dose of study drug and had evaluable PK data.</population>
          <units>nanogram x hour/milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">At doses less than 1.6 mg, the AUC(0-â) could not be reliably quantified.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">At doses less than 1.6 mg, the AUC(0-â) could not be reliably quantified.</measurement>
                    <measurement group_id="O3" value="60.6" spread="49"/>
                    <measurement group_id="O4" value="197" spread="38"/>
                    <measurement group_id="O5" value="393" spread="84"/>
                    <measurement group_id="O6" value="1680" spread="34"/>
                    <measurement group_id="O7" value="49.9" spread="41"/>
                    <measurement group_id="O8" value="102" spread="111"/>
                    <measurement group_id="O9" value="575" spread="62"/>
                    <measurement group_id="O10" value="38.6" spread="25"/>
                    <measurement group_id="O11" value="151" spread="54"/>
                    <measurement group_id="O12" value="1020" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic(PD) Biomarker: Plasma Minimum Amyloid-Beta Peptide (A-beta) 1-40 Concentration</title>
        <description>Plasma minimum A-beta 1-40 concentration or nadir concentration (Cnadir) is defined as the lowest concentration of plasma A-beta 1-40 following dose administration.</description>
        <time_frame>Part A Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 postdose; Part C Day 14: Predose 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 120, 168, and 216 postdose</time_frame>
        <population>All participants in Part A, Periods 1-3 and Part C, Period 3, who received at least one dose of study drug and had evaluable PD data analyzed per protocol. Participants in Part B and D were not assessed per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A Placebo</title>
            <description>Single dose of placebo given PO in capsule form in Period 1-4.</description>
          </group>
          <group group_id="O2">
            <title>Part A 0.1mg LY3202626</title>
            <description>Single dose 0.1mg LY3202626 given PO in Period 1 Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part A 0.4mg LY3202626</title>
            <description>Single dose of 0.4mg LY3202626 given PO in Period 1 Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part A 1.6 mg LY3202626</title>
            <description>Single dose of 1.6mg LY3202626 given PO in Period 2 Cohort 1.</description>
          </group>
          <group group_id="O5">
            <title>Part A 5mg LY3202626</title>
            <description>Single dose of 5mg LY3202626 given PO in Period 2 Cohort 2.</description>
          </group>
          <group group_id="O6">
            <title>Part A 15mg LY3202626</title>
            <description>Single dose of 15mg LY3202626 given PO in Period 3 and Period 4 Cohort 1.</description>
          </group>
          <group group_id="O7">
            <title>Part A 45mg LY3202626</title>
            <description>Single dose of 45mg LY3202626 given PO in Period 3 Cohort 2.</description>
          </group>
          <group group_id="O8">
            <title>Part C Placebo</title>
            <description>Multiple doses of placebo given PO once daily for 14 days.</description>
          </group>
          <group group_id="O9">
            <title>Part C 1mg LY3202626 QD</title>
            <description>Multiple doses of 1mg LY3202626 in given PO once daily for 14 days.</description>
          </group>
          <group group_id="O10">
            <title>Part C 6mg LY3202626 QD</title>
            <description>Multiple doses of 6mg LY3202626 given PO once daily for 14 days.</description>
          </group>
          <group group_id="O11">
            <title>Part C 26mg LY3202626 QD</title>
            <description>Multiple doses of 26mg LY3202626 given PO once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic(PD) Biomarker: Plasma Minimum Amyloid-Beta Peptide (A-beta) 1-40 Concentration</title>
          <description>Plasma minimum A-beta 1-40 concentration or nadir concentration (Cnadir) is defined as the lowest concentration of plasma A-beta 1-40 following dose administration.</description>
          <population>All participants in Part A, Periods 1-3 and Part C, Period 3, who received at least one dose of study drug and had evaluable PD data analyzed per protocol. Participants in Part B and D were not assessed per protocol.</population>
          <units>Picogram per milliliter (pg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="35.1"/>
                    <measurement group_id="O2" value="58.1" spread="150"/>
                    <measurement group_id="O3" value="61.8" spread="25.6"/>
                    <measurement group_id="O4" value="33.4" spread="62.0"/>
                    <measurement group_id="O5" value="25.2" spread="16.8"/>
                    <measurement group_id="O6" value="17.0" spread="33.6"/>
                    <measurement group_id="O7" value="7.93" spread="42.0"/>
                    <measurement group_id="O8" value="84.6" spread="26.5"/>
                    <measurement group_id="O9" value="24.0" spread="33.1"/>
                    <measurement group_id="O10" value="5.80" spread="51.9"/>
                    <measurement group_id="O11" value="4.2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Biomarker: Cerebral Spinal Fluid (CSF) Minimum Amyloid-beta Peptide (A-beta) 1-40 Concentration</title>
        <description>CSF minimum A-beta 1-40 concentration or nadir concentration (Cnadir) is defined as the lowest concentration of CSF A-beta 1-40 following dose administration.</description>
        <time_frame>Part B: -4, -2, Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 24, 28, 32, and 36 hours postdose</time_frame>
        <population>All participants in Part B who received at least one dose of study drug and had evaluable CSF PD data analyzed per protocol. Participants in Part A, C and D were not assessed per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B Placebo</title>
            <description>Single dose of placebo given PO in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Part B 1.6 mg LY3202626</title>
            <description>Single dose of 1.6mg LY3202626 given PO in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Part B 6mg LY3202626</title>
            <description>Single dose of 6mg LY3202626 given PO in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Part B 26mg LY3202626</title>
            <description>Single dose of 26mg LY3202626 given PO in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Biomarker: Cerebral Spinal Fluid (CSF) Minimum Amyloid-beta Peptide (A-beta) 1-40 Concentration</title>
          <description>CSF minimum A-beta 1-40 concentration or nadir concentration (Cnadir) is defined as the lowest concentration of CSF A-beta 1-40 following dose administration.</description>
          <population>All participants in Part B who received at least one dose of study drug and had evaluable CSF PD data analyzed per protocol. Participants in Part A, C and D were not assessed per protocol.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7980" spread="53.8"/>
                    <measurement group_id="O2" value="5700" spread="22.3"/>
                    <measurement group_id="O3" value="5770" spread="41.8"/>
                    <measurement group_id="O4" value="2980" spread="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: CSF Concentration of LY3202626</title>
        <time_frame>Part C: Day 15 at 24 hours +/- 4 hours (hr) postdose</time_frame>
        <population>All participants in Part C who received at least one dose of study drug and had evaluable CSF PK data per protocol. Participants in Part A, B and D were not assessed per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C 1mg LY3202626</title>
            <description>Multiple doses of 1mg LY3202626 given PO once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Part C 6 mg LY3202626</title>
            <description>Multiple doses of 6mg LY3202626 given PO once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Part C 26mg LY3202626</title>
            <description>Multiple doses of 26mg LY3202626 given PO once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: CSF Concentration of LY3202626</title>
          <population>All participants in Part C who received at least one dose of study drug and had evaluable CSF PK data per protocol. Participants in Part A, B and D were not assessed per protocol.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0648" spread="46.2"/>
                    <measurement group_id="O2" value="0.202" spread="48.9"/>
                    <measurement group_id="O3" value="1.26" spread="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Biomarker: Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid-beta Peptide (A-beta) 1-40 Concentration</title>
        <description>CSF AÎ²1-40 change from baseline at Day 15 endpoint, 24 hours postdose (+/- 4 hours) following multiple doses of LY3202626.</description>
        <time_frame>Parts C: Baseline, Day 15</time_frame>
        <population>All participants in Part C who received at least one dose of study drug and had evaluable CSF PD data analyzed. Participants in Part A, B and D were not assessed per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C Placebo</title>
            <description>Multiple doses of placebo given PO once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Part C 1mg LY3202626</title>
            <description>Multiple doses of 1mg LY3202626 given PO once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Part C 6mg LY3202626</title>
            <description>Multiple doses of 6mg LY3202626 given PO once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Part C 26mg LY3202626</title>
            <description>Multiple doses of 26mg LY3202626 given PO once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Biomarker: Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid-beta Peptide (A-beta) 1-40 Concentration</title>
          <description>CSF AÎ²1-40 change from baseline at Day 15 endpoint, 24 hours postdose (+/- 4 hours) following multiple doses of LY3202626.</description>
          <population>All participants in Part C who received at least one dose of study drug and had evaluable CSF PD data analyzed. Participants in Part A, B and D were not assessed per protocol.</population>
          <units>percent change in concentration</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="16.8"/>
                    <measurement group_id="O2" value="-50.1" spread="8.56"/>
                    <measurement group_id="O3" value="-75.7" spread="7.38"/>
                    <measurement group_id="O4" value="-93.7" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Part A, B, and C Placebo</title>
          <description>Single dose of placebo given PO in in capsule form, Part A and B. Multiple doses of placebo given PO in capsule form, Part C.</description>
        </group>
        <group group_id="E2">
          <title>Part A 0.1mg LY3202626</title>
          <description>Single dose of 0.1mg LY3202626 given PO in in capsule form.</description>
        </group>
        <group group_id="E3">
          <title>Part A 0.4mg LY3202626</title>
          <description>Single dose of 0.4mg LY3202626 given PO in in capsule form.</description>
        </group>
        <group group_id="E4">
          <title>Part A 0.4mg LY3202626 + 200mg Itraconazole</title>
          <description>Single dose of 0.4mg LY3202626 +200mg Itraconazole given PO in in capsule form.</description>
        </group>
        <group group_id="E5">
          <title>Part C 1mg LY3202626 QD</title>
          <description>Multiple daily dose of 1mg LY3202626 given PO in in capsule form.</description>
        </group>
        <group group_id="E6">
          <title>Part A and B 1.6mg LY3202626</title>
          <description>Single dose of 1.6mg LY3202626 given PO in in capsule form..</description>
        </group>
        <group group_id="E7">
          <title>Part A 5mg LY3202626</title>
          <description>Single dose of 5mg LY3202626 given PO in in capsule form.</description>
        </group>
        <group group_id="E8">
          <title>Part C and Part D 6mg LY3202626 QD</title>
          <description>Multiple daily dose of 6mg LY3202626 given PO in capsule form.</description>
        </group>
        <group group_id="E9">
          <title>Part A and B 10mg LY3202626</title>
          <description>Single dose of 10mg LY3202626 given PO in capsule form.</description>
        </group>
        <group group_id="E10">
          <title>Part A 15mg LY3202626</title>
          <description>Single dose of 15mg LY3202626 given PO in capsule form.</description>
        </group>
        <group group_id="E11">
          <title>Part B and C 26mg LY3202626</title>
          <description>Single dose of 26mg LY3202626 given PO in capsule form, Part B. Multiple daily dose of 26mg LY3202626 in in capsule form, Part C.</description>
        </group>
        <group group_id="E12">
          <title>Part A 45mg LY3202626</title>
          <description>Single dose of 45mg LY3202626 given PO in in capsule form.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E11" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Postural orthostatic tachycardia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="9" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" events="8" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E9" events="12" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="8" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="5" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

